Source: International Congress 2015 – New data on established treatments for asthma and COPD
Disease area: Airway diseases

Abstract

Introduction: The WISDOM study (NCT00975195) showed that in patients with severe to very severe COPD receiving tiotropium + salmeterol, risk of moderate or severe exacerbations was non-inferior in patients discontinuing inhaled corticosteroids (ICS) compared to those continuing ICS. However, patients in the ICS-withdrawal arm had a small reduction in trough FEV₁ (43 mL; p<0.01). We analysed post hoc the relationship of the change in FEV₁ in both treatment arms to moderate or severe exacerbations.Methods: All patients were categorised into three groups according to the tertiles (33rd and 67th percentiles) of the change from baseline in trough FEV₁ after 1 year of treatment; decrease (<-130 mL), medium change (³-130 mL to <20 mL) or increase (³20 mL). The change groups were analysed using descriptive statistics.Results: The percentage of patients with moderate or severe on-treatment exacerbation was similar between the decrease and increase FEV₁ change groups, and ~10% higher in the medium change group (Table). These findings were similar in the ICS and ICS-withdrawal arms.Conclusions: In the WISDOM study, no apparent relationship was observed between the magnitude of change in FEV₁ and exacerbations over 1 year of treatment in patients with severe to very severe COPD receiving tiotropium + salmeterol, with or without ICS therapy.



Funding: Boehringer Ingelheim.


Rating:

Share or cite this content

Citations should be made in the following way:
Henrik Watz (Grosshansdorf, Germany), Henrik Watz, Helgo Magnussen, Anne Kirsten, Kay Tetzlaff, Helen Finnigan, Bernd Disse, Eric Bateman. Lung function change and exacerbations in patients with COPD in the WISDOM study. Eur Respir J 2015; 46: Suppl. 59, 1019

Member's Comments

No comment yet.

Related content which might interest you: Can emphysema predict exacerbations and changes in PFTs in COPD? Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 Spirometry quality in patients with COPD exacerbation, related to the “frequent exacerbator” phenotype Source: Annual Congress 2013 –Reference, reliability and risk: advances in lung function Year: 2013 The predictors for COPD exacerbations using remote patient monitoring Source: International Congress 2015 – Clinical assessment in asthma and COPD Year: 2015 The clinical significance and frequency of bronchiectasis in COPD patients Source: International Congress 2016 – Monitoring comorbidities Year: 2016 QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Frequency of COPD exacerbations and severity of COPD Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 A pilot study of CPAP therapy for excessive dynamic airway collapse during acute exacerbation of COPD Source: International Congress 2014 – COPD - from biomarkers to novel therapeutic opportunities Year: 2014 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Symptom profile of exacerbations in earlier and later COPD Source: Annual Congress 2013 –Asthma and COPD: diseases with different phenotypes Year: 2013 Clinical characteristics of patients with clinically-diagnosed COPD exacerbations but without concomitant airflow limitation Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015 Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 The relationship between 24-hour symptoms and COPD exacerbations: Results from ASSESS Source: International Congress 2014 – COPD exacerbations Year: 2014 Impact of bronchiectasis on duration of hospitalization in patients with exacerbations of COPD Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations Year: 2015 Real life assessment of inhaler use and acute exacerbations in 2935 COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 COPD exacerbations occur more frequently in women – Data from the Bergmannsheil cohort Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations Year: 2015 A global survey conducted to determine frequency of exacerbations in COPD patients Source: Annual Congress 2013 –COPD treatment Year: 2013 Pneumonia risk in COPD patients on long term inhaled corticosteroids – Data from the European COPD audit<% Source: Annual Congress 2013 –Guidelines and exacerbations Year: 2013